Time To Add-On Medication Use for Patients with Type 2 Diabetes Mellitus (T2DM) Who Failed Metformin Monotherapy

被引：0
|
作者：
Qiu, Ying
Fu, Alex Z.
Radican, Larry
机构：
来源：
DIABETES | 2010年 / 59卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：A70 / +
页数：2
相关论文
共 50 条
  • [31] The Cost-Effectiveness of Canagliflozin (CANA) vs. Sitagliptin as an Add-on to Metformin (MET) in the Treatment of Type 2 Diabetes Mellitus (T2DM) in the US
    Martin, Silas
    Neslusan, Cheryl
    Vo, Lien
    Teschemaker, Anna
    Johansen, Pierre
    Willis, Michael
    DIABETES, 2014, 63 : A310 - A310
  • [32] COST-EFFECTIVENESS ANALYSIS OF CANAGLIFLOZIN (CANA) VERSUS DAPAGLIFLOZIN (DAPA) AS AN ADD-ON TO METFORMIN (MET) IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM) IN THE UNITED STATES
    Neslusan, C.
    Teschemaker, A.
    Martin, S.
    Willis, M.
    Johansen, P.
    VALUE IN HEALTH, 2014, 17 (03) : A248 - A248
  • [33] DIABETES Add-on to metformin in T2DM-linagliptin or glimepiride?
    Christensen, Mikkel
    Knop, Filip K.
    NATURE REVIEWS ENDOCRINOLOGY, 2012, 8 (10) : 576 - 578
  • [34] Trends in add-on medications following metformin monotherapy for type 2 diabetes
    Swart, Elizabeth C. S.
    Neilson, Lynn M.
    Munshi, Kiraat
    Peasah, Samuel K.
    Henderson, Rochelle
    Good, Chester B.
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2022, 28 (11): : 1253 - 1259
  • [35] Effect of Colesevelam HCl (COL) as an Add-On to Pioglitazone (PIO) on Lipid Particles in Type 2 Diabetes Mellitus (T2DM)
    Jones, Michael R.
    Ford, Daniel M.
    Baz-Hecht, Merav
    Tao, Ben
    Truitt, Kenneth E.
    Chou, Hubert S.
    DIABETES, 2013, 62 : A302 - A302
  • [36] Empagliflozin as Add-on to Linagliptin and Metformin in Patients with Type 2 Diabetes (T2DM): Subgroup Analysis by Region in a 24-Week Randomized Trial
    Wanner, Christoph
    Naderali, Ebrahim
    Maldonaldo, Mario
    Del Parigi, Angelo
    Toorawa, Robert
    Lee, Christopher
    DIABETES, 2016, 65 : A288 - A289
  • [37] Augmentation Patterns Amongst Metformin Initiators with Type 2 Diabetes Mellitus (T2DM)
    Gopalakrishnan, Chandrasekar
    Schneeweiss, Sebastian
    Seeger, John D.
    Liu, Jun
    Patorno, Elisabetta
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2016, 25 : 26 - 27
  • [38] Efficacy of metformin alone or in combination with insulin in pediatric patients with type 2 diabetes mellitus (T2DM)
    Weinzimer, SA
    McKnight, WJ
    Murphy, K
    Jawad, AF
    Celona-Jacobs, N
    Haque, A
    Katz, LEL
    DIABETES, 2001, 50 : A68 - A68
  • [39] Empagliflozin as add-on to metformin in patients with Type 2 diabetes
    Merker, L.
    Haering, H. U.
    Christiansen, A. Vedel
    Roux, F.
    Salsali, A.
    Kim, G.
    Meinicke, T.
    Woerle, H. J.
    Broedl, U. C.
    DIABETIC MEDICINE, 2015, 32 : 89 - 89
  • [40] Target Achievement and Quality Measure (QM) Attainment with Titrated Canagliflozin (CANA) in Patients with Type 2 Diabetes Mellitus (T2DM) as Add-on to Metformin (MET) plus Sitagliptin (SITA)
    Seufert, Jochen
    Aggarwal, Naresh
    Bailey, Robert
    Cao, Anjun
    Fung, Albert
    Pfeifer, Michael
    Alba, Maria
    Rodbard, Helena W.
    DIABETES, 2016, 65 : A308 - A308
12345